Dr. Jerry McMahon is the President and CEO of STORM Therapeutics, a Cambridge, UK biotech pioneering drugs that target RNA modifying enzymes. A biochemist-turned-operator with more than 30 years in oncology drug development, he has led biotechs from bench to IPO, helped bring the cancer drug sunitinib (Sutent) to patients, and now steers STORM's first-in-class METTL3 inhibitor STC-15 through the clinic - the first RNA modification enzyme inhibitor ever to enter human trials.
STORM Therapeutics is a Cambridge, UK biotechnology company pioneering the field of RNA epigenetics. It designs small-molecule inhibitors of RNA-modifying enzymes to treat cancer and other diseases. Its lead drug, STC-15, is the first RNA-modifying enzyme inhibitor to reach human clinical trials, now in a Phase 2 study for sarcoma.